To the full analysis
Ironwood Pharmaceuticals stock: growth
IRWDIronwood Pharmaceuticals reported $296.15M in revenue for fiscal 2025, down 15.7% on the prior year, down 5.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
27%
per year from 2006 to 2025, per share 7.8%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | −5.3% | 7.1% | 27.0% |
| Revenue per share | −5.7% | 5.7% | 7.8% |
| Earnings | −25.7% | no data | no data |
| Earnings per share | −25.9% | no data | no data |
| Free cash flow | −5.3% | no data | no data |
| Free cash flow per share | −5.7% | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $3.14M | −$37.18M | −$36.35M |
| 2007 | $10.46M | −$52.75M | −$9.41M |
| 2008 | $22.22M | −$53.87M | −$51.13M |
| 2009 | $36.1M | −$71.19M | −$8.04M |
| 2010 | $43.86M | −$52.98M | −$85.12M |
| 2011 | $65.87M | −$64.85M | −$84.92M |
| 2012 | $150.25M | −$72.62M | −$83.61M |
| 2013 | $22.88M | −$272.81M | −$282.95M |
| 2014 | $76.44M | −$189.62M | −$159.11M |
| 2015 | $149.56M | −$142.67M | −$110.98M |
| 2016 | $273.96M | −$81.71M | −$129.64M |
| 2017 | $298.28M | −$116.94M | −$103.77M |
| 2018 | $346.64M | −$282.37M | −$79.5M |
| 2019 | $428.41M | $21.51M | $3.54M |
| 2020 | $389.52M | $106.18M | $166.99M |
| 2021 | $413.75M | $528.45M | $261.63M |
| 2022 | $410.6M | $175.07M | $273.63M |
| 2023 | $442.74M | −$1B | $183.15M |
| 2024 | $351.41M | $880K | $103.41M |
| 2025 | $296.15M | $24.02M | $127.01M |
Revenue by region
Where Ironwood Pharmaceuticals, Inc. generates its revenue.
- North America99%
- Europe and Other1%
- Other< 1%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|
| North America | $433.24M | $343.15M | $292.36M | 98.7% |
| Europe and Other | $2.8M | $3.24M | $3.63M | 1.2% |
| Other | $6.69M | $5.02M | $0 | 0% |
| Total revenue | $442.74M | $351.41M | $296.15M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 12 Nov 2026, previously Neutral
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.